https://www.science.org/content/article/first-polio-cases-linked-new-oral-vaccine-detected-africa Advertisement * * news * careers * commentary * Journals * Covid-19 Science Science * * * Log in * Become A Member [science] science [sciadv] science advances [sciimmunol] science immunology [scirobotics] science robotics [signaling] science signaling [stm] science translational medicine [spj-cover-1672180580773] science partner journals Quick Search anywhere Enter Search Term[ ] Quick Search in Journals Enter Search Term[ ] Quick Search in Journals Enter Search Term[ ] Quick Search in Journals Enter Search Term[ ] Quick Search in Journals Enter Search Term[ ] Quick Search in Journals Enter Search Term[ ] Quick Search in Journals Enter Search Term[ ] Searching: Anywhere AnywhereScienceScience AdvancesScience ImmunologyScience Robotics Science SignalingScience Translational Medicine Advanced Search Search Trending Terms: * covid-19 * climate * monkeypox * abortion * perovskite Log In Become A Member Quick Search anywhere Enter Search Term[ ] science.org * Custom publishing * collections * videos * podcasts * blogs * visualizations * prizes and awards * authors & reviewers * librarians * advertisers * about * help * * * * * * AAAS Logo * Terms of Service * Privacy Policy * Accessibility * News Home * All News * ScienceInsider * News Features GET OUR E-ALERTS HomeNewsScienceInsiderPolio cases in Africa linked to new oral vaccine Back To ScienceInsider * ScienceInsider * Africa Polio cases in Africa linked to new oral vaccine Improved vaccine is not reaching enough children * 20 Mar 2023 * 1:25 PM * ByLeslie Roberts A child is administered the nOPV2 polio vaccine in Nigeria A child in Nigeria receives novel oral polio vaccine type 2, which is designed to be less likely to mutate into a virulent form.World Health Organization Nigeria Share: * Twitter * Linked In * Facebook * Reddit * Wechat * Email Last week, the Global Polio Eradication Initiative (GPEI) reported seven children, six in the Democratic Republic of the Congo (DRC) and one in neighboring Burundi, had recently been paralyzed by poliovirus strains derived from a vaccine meant to prevent the disease. Unfortunately, such cases are so common--786 were reported last year in Africa, Yemen, and elsewhere--that these seven might not have stood out against the noise. But there was a key difference, GPEI said in a 16 March statement: These are the first cases linked to a new polio vaccine that was painstakingly designed to avoid just this problem. Known as novel oral polio vaccine type 2 (nOPV2), it was rolled out 2 years ago this month, and public health experts have been closely monitoring whether its use could also spark outbreaks on rare occasions. "It's disappointing but not entirely unexpected," says Aidan O'Leary, who heads GPEI. To Simona Zipursky of the World Health Organization, who co-chairs GPEI's nOPV2 working group, the question for the past 2 years has been when, not whether, such cases would occur. "But you always hope you are wrong," she says. Although the novel vaccine is not a magic bullet, the data from the initial rollout show it's far better than the one it has largely replaced, monovalent OPV2 (mOPV2), Zipursky and others say. The risk of sparking outbreaks with nOPV2 is "much, much lower," says Ananda Bandyopadhyay, deputy director of technology, research, and policy for polio at the Bill & Melinda Gates Foundation and the other co-chair of the GPEI working group. Cheap and easy to use, Albert Sabin's OPV is hands down the best vaccine for eliminating polio in poor settings where clean water and sanitation are lacking. Children shed the weakened virus from the vaccine in their stool for a short time after they receive the oral drops, conferring immunity even on those who are not vaccinated. The problem is that in areas where polio vaccination rates are low, in rare cases the vaccine virus can continue to spread among un- or underimmunized people for months, accumulating enough mutations to revert to its paralytic form. This happens most often with poliovirus type 2, one of three serotypes. For years now, GPEI has been chasing its tail, quashing one type 2 outbreak with mOPV2 only to seed new outbreaks. In 2011, an international team of researchers, funded by the Gates foundation, began working on a technical fix. Starting with the same type 2 Sabin vaccine virus, they tweaked its genome in several places to make it less likely to revert. The hope was that nOPV2 would not seed new outbreaks--or at least do so much less frequently than mOPV2. Clinical and preclinical data looked good--the vaccine was just as safe and effective as mOPV2 and much more genetically stable, Bandyopadhyay says. But because these reversions are rare events, the new vaccine's true worth could not be known until it was used widely under close scrutiny. Since March 2021, GPEI and its country partners have administered almost 600 million doses of the new vaccine to respond to outbreaks in 28 countries--until now, without a hitch. The seven cases of paralysis arose from two separate "emergences"--in other words, two vaccine viruses reverted independently, in South Kivu and Tanganyika provinces in the DRC, and then began to spread. The one case in Burundi, in Bujumbura Rural province, is linked to the South Kivu strain; that virus has also been detected in five sewage samples in a neighboring province. "This is clearly an extremely rare event," O'Leary says. Going forward, the job is to figure out just how rare, Zipursky says. "We will continue to gather data to get a true sense of [nOPV2's] genetic stability." A preliminary analysis suggests that if mOPV2 had been used instead at this broad scale, an estimated 30 to 40 emergences would have occurred as opposed to two, Bandyopadhyay says. Vaccine experts are now weighing the relative merits of the two oral options, and that's important, O'Leary says. But he stresses that the problem of low vaccination coverage should get equal or greater attention. Bandyopadhyay agrees. "If there is persistently poor immunization coverage in a community, there is always a risk that a live, attenuated vaccine virus will revert." Both mOPV2 and nOPV2 have stopped many outbreaks where the vaccination campaigns are of high quality. But those can be hard to pull off in parts of the DRC and Burundi. Indeed, GPEI has identified eastern DRC, where these paralytic viral variants arose, as one of seven places globally at highest risk for polio outbreaks--and where once they start, they can be extremely hard to stop. The DRC is rocked by conflict and political instability, which makes it difficult to reach many children with vaccines. It has also been battling simultaneous disease outbreaks, all vying for priority. Routine vaccination rates are low. "GPEI needs to dig deep and work through all the surveillance data in both countries to understand what is happening with the [nOPV2] vaccine," O'Leary says. At the same time, he says, the program needs to intensify its efforts to reach all the children being missed by that vaccine. --------------------------------------------------------------------- doi: 10.1126/science.adh8837 Relevant tags: AfricaHealth About the author Leslie Roberts Leslie Roberts Author Leslie Roberts is a former news editor at Science. --------------------------------------------------------------------- More from news a man sitting on a bed with his arms crossed over his chest while another man monitors him 21 Mar 2023 People who catch Omicron are less likely to get Long Covid By * Jennifer Couzin-Frankel Steven Newmaster 20 Mar 2023 After misconduct claims, star botanist has second paper retracted By * Charles Piller Image with rings showing crater width on map of Kazakhstan 20 Mar 2023 Earth at higher risk of big asteroid strike, satellite data suggest By * Paul Voosen View more Got a tip for Science's news department? Connect Subscribe to News from Science Don't yet have access? Subscribe to News from Science for full access to breaking news and analysis on research and science policy. Subscribe Advertisement ScienceInsider a man sitting on a bed with his arms crossed over his chest while another man monitors him 21 Mar 2023By * Jennifer Couzin-Frankel People who catch Omicron are less likely to get Long Covid Steven Newmaster 20 Mar 2023By * Charles Piller After misconduct claims, star botanist has second paper retracted A child is administered the nOPV2 polio vaccine in Nigeria 20 Mar 2023By * Leslie Roberts Polio cases in Africa linked to new oral vaccine Members of staff of the Wuhan Hygiene Emergency Response Team conduct searches at the closed Huanan Seafood Wholesale Market in the city of Wuhan on January 11, 2020. 17 Mar 2023By * Jon Cohen 'It's inexcusable.' WHO blasts China for not disclosing potential data on COVID-19's origin View more Advertisement Sifter Human oocyte with Zona pellucida, in vitro fertilization, and assisted reproductive technology 16 Mar 2023By * Claudia Lopez Lloreda Healthy mice born from 'male' eggs illustration of mice dancing 9 Mar 2023By * Claudia Lopez Lloreda A hormone shot helps mice sober up A satellite trail crossing close to galaxy ARP248 3 Mar 2023By * Daniel Clery Satellites spoiling more and more Hubble images Pablo Neruda 15 Feb 2023By * Claudia Lopez Lloreda Pablo Neruda was poisoned to death, a new forensic report suggests View more RecommendedClose In DepthAugust 2016 New polio cases in Nigeria spur massive response News of the WeekSeptember 2007 Vaccine-Related Polio Outbreak in Nigeria Raises Concerns In DepthNovember 2020 New polio vaccine could boost faltering eradication drive News FocusApril 2007 Moderate Success for New Polio Vaccine Advertisement SIGN UP FOR NEWS FROM SCIENCE DAILY HEADLINES Get more great content like this delivered right to you! Sign up Support nonprofit science journalism Help News from Science publish trustworthy, high-impact stories about research and the people who shape it. Please make a tax-deductible gift today. Donate Not Now [logo-dark] x (*) $50 ( ) $75 ( ) $100 ( ) Other $ [ ] Please enter a valid email (*) Single ( ) Monthly Email: [ ] Please enter a valid email Country: [United States ] [ ] I also wish to receive emails from AAAS/Science and Science advertisers, including information on products, services and special offers which may include but are not limited to news, careers information & upcoming events. Donate now Support nonprofit science journalism If we've learned anything from the COVID-19 pandemic, it's that we cannot wait for a crisis to respond. Science and AAAS are working tirelessly to provide credible, evidence-based information on the latest scientific research and policy, with extensive free coverage of the pandemic. Your tax-deductible contribution plays a critical role in sustaining this effort. Charitable Disclosures Loading... Skip slideshow Follow Us * * * * * * * NEWS * All News * ScienceInsider * News Features * Subscribe to News from Science * News from Science FAQ * About News from Science * CAREERS * Careers Articles * Find Jobs * Employer Profiles * COMMENTARY * Opinion * Analysis * Blogs * JOURNALS * Science * Science Advances * Science Immunology * Science Robotics * Science Signaling * Science Translational Medicine * Science Partner Journals * AUTHORS & REVIEWERS * Information for Authors * Information for Reviewers * LIBRARIANS * Manage Your Institutional Subscription * Library Admin Portal * Request a Quote * Librarian FAQs * ADVERTISERS * Advertising Kits * Custom Publishing Info * Post a Job * RELATED SITES * AAAS.org * AAAS Communities * EurekAlert! * Science in the Classroom * ABOUT US * Leadership * Work at AAAS * Prizes and Awards * HELP * FAQs * Access and Subscriptions * Order a Single Issue * Reprints and Permissions * TOC Alerts and RSS Feeds * Contact Us Follow Us * * * * * * AAAS logo (c) 2023 American Association for the Advancement of Science. All rights reserved. AAAS is a partner of HINARI, AGORA, OARE, CHORUS, CLOCKSS, CrossRef and COUNTER. back to top * Terms of Service * Privacy Policy * Accessibility Thank you for reading News fromScience. You have reached your limit of 3 free news stories in the past 30 days. To gain unlimited access to News fromScience, pleaseLog inor subscribe to News from Science. AAAS Members canLog infor unlimited access. $2.99/Month$25/YearFrequently Asked Questions